InvestorsHub Logo
Followers 46
Posts 2450
Boards Moderated 0
Alias Born 04/17/2019

Re: The Lawman post# 40693

Thursday, 05/09/2019 7:30:09 AM

Thursday, May 09, 2019 7:30:09 AM

Post# of 233568
Dance Biopharma made a mistake going into the inhalable insulin market. just ask MNKD.

What happened to Matinas Biopharma's game changing catalysts in 2016? It's lipid nanocrystal technology is not unique (Ascendia has a jump start on that). MAT2203 has a fairly tight market, small target population, small profitability (if any). They should have started development with MAT2501 first which has a much larger market and a greater chance of success.

At least going by share performance or product choice neither are stellar.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News